AstraZeneca Showcases Oncology Breakthroughs at ASCO 2025, Reinforcing Mission to Eliminate Cancer as a Cause of Death AstraZeneca will present new data from over 80 abstracts at the 2025 American…
Roche Presents Positive ODAC Discussion on Columvi® Combination Therapy for Aggressive Lymphoma Basel, Switzerland – May 21, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food…
FDA Under Makary Eyes New Pathway for Rare Disease Drugs Amid Debate Over Feasibility and Safety While the U.S. Food and Drug Administration (FDA) under new Health and Human Services…
FDA and NIH Push Toward Replacing Animal Testing with AI and Human Organoids In a groundbreaking move, the FDA—under Commissioner Marty Makary—announced plans in April to significantly reduce animal testing…
Why Deregulation Won’t Deliver for the Pharmaceutical Industry The current U.S. presidential administration under Donald Trump has begun eliminating federal regulatory staff and announced plans to dramatically scale back regulations.…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science proudly announced the winners of the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college STEM competition.…
Novo Nordisk has announced significant leadership changes, including the upcoming departure of CEO Lars Fruergaard Jørgensen. As part of a mutual agreement with the Novo Nordisk Board of Directors, Jørgensen…
As the FDA gears up for a jam-packed Oncologic Drugs Advisory Committee (ODAC) meeting next week, internal sources are raising concerns about the agency’s preparedness. According to an FDA insider…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a significant legal victory after a jury in the U.S. District Court for the District of Delaware ruled that Amgen Inc. violated multiple antitrust…
Novartis is set to unveil data from 60 company- and investigator-sponsored abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress.…
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today reported that its Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) has met its primary endpoint, showing a statistically significant…
Shockwave Medical, Inc., now part of Johnson & Johnson MedTech and a global leader in circulatory restoration, announced today that it will showcase data from 23 company-sponsored studies—including three late-breaking…